Catherine Van Poznak

Author

Also Known As

Bryan J. Traughber, C Van Poznak, C. H. Van Poznak, C. H. van Poznak, C. Van Poznak, C. van Poznak, C.H. Van Poznak, Catherine H Van Poznak, Catherine H. Van Poznak, Catherine Van Poznak

240

Publications

14.2K

Citations

H-Index

Concepts

All Affiliations

University of Michigan Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Michigan Center for Translational Pathology Dana-Farber Cancer Institute

About

Catherine Van Poznak is an author at University of Michigan specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	44	3.7K
2	Health Sciences	15	18	851
3	Nursing	3	3	136
4	Engineering	1	1	17
5	Allergy	1	1	15

Catherine Van Poznak

Publications

8.3K

Citations

H-Index

Page 1

	Year	Citations
Activating ESR1 mutations in hormone-resistant metastatic breast cancer Dan R. Robinson, Yi-Mi Wu, Pankaj Vats, Nature Genetics Breast OncologyMedicineBreast CancerEsr1 MutationsCancer Genetics	2013	1.1K
Bone health in cancer: ESMO Clinical Practice Guidelines Robert E. Coleman, Peyman Hadji, Jean‐Jacques Body, Annals of Oncology	2020	481
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Catherine Van Poznak, Mark R. Somerfield, Robert C. Bast, Journal of Clinical Oncology	2015	386
American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer Catherine Van Poznak, Sarah Temin, Gary C. Yee, Journal of Clinical Oncology	2011	342
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases Rachel A. Freedman, Rebecca Gelman, Carey K. Anders, Journal of Clinical Oncology	2019	332
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update Ian E. Krop, Nofisat Ismaila, Fabrice André, Journal of Clinical Oncology Prognostic BiomarkersNode-negative Breast CancerBreast OncologyMedicineCancer Management	2017	312
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis Xin Lü, Qiongqing Wang, Guohong Hu, Genes & Development	2009	302
C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells Roger R. Gomis, Claudio R. Alarcón, Cristina Nadal, Cancer Cell Breast OncologyMedicineCancer Cell BiologyBreast CancerTgfβ Cytostatic Response	2006	269
Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study Arti Hurria, Carol L. Rosen, Clifford A. Hudis, Journal of the American Geriatrics Society	2006	262
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx Fabrice André, Nofisat Ismaila, N. Lynn Henry, Journal of Clinical Oncology	2019	227

Page 1